(Q46729832)

24 December 2017

title

Plasma homocysteine levels in L-dopa-treated Parkinson's disease patients with cognitive dysfunctions (English)

1 reference

24 December 2017

1 reference

10

1 reference

24 December 2017

Giovanni Defazio

6

object named as

Giovanni Defazio

1 reference

24 December 2017

Stefano Zoccolella

1

1 reference

24 December 2017

Paolo Lamberti

2

1 reference

24 December 2017

Giovanni Iliceto

3

1 reference

24 December 2017

Cosimo Diroma

4

1 reference

24 December 2017

Elio Armenise

5

1 reference

24 December 2017

Simona V Lamberti

7

1 reference

24 December 2017

Angela Fraddosio

8

1 reference

24 December 2017

Michele de Mari

9

1 reference

24 December 2017

publication date

1 January 2005

1 reference

24 December 2017

Clinical Chemistry and Laboratory Medicine

published in

1 reference

24 December 2017

volume

43

1 reference

24 December 2017

page(s)

1107-1110

1 reference

24 December 2017

issue

10

1 reference

24 December 2017

Homocysteine in Alzheimer disease and vascular dementia

cites work

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2005.193

Effects of homocysteine on the dopaminergic system and behavior in rodents

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2005.193

Nigral endothelial dysfunction, homocysteine, and Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2005.193

Elevated plasma homocysteine level in patients with Parkinson disease: motor, affective, and cognitive associations

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2005.193

Folate deficiency and homocysteine induce toxicity in cultured dorsal root ganglion neurons via cytosolic calcium accumulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2005.193

Homocysteine and levodopa: should Parkinson disease patients receive preventative therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2005.193

Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2005.193

Hypertrophy of IMC of carotid artery in Parkinson's disease is associated with L-DOPA, homocysteine, and MTHFR genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2005.193

Hyperhomocysteinemia, vascular function and atherosclerosis: effects of vitamins

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2005.193

Homocysteine and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2005.193

Plasma homocysteine levels in Parkinson's disease: role of antiparkinsonian medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2005.193

Levodopa-induced hyperhomocysteinaemia in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2005.193

Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2005.193

Hyperhomocysteinemia in L-dopa treated Parkinson's disease patients: effect of cobalamin and folate administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2005.193

Modest increase in plasma homocysteine follows levodopa initiation in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2005.193

Moderately elevated plasma homocysteine, methylenetetrahydrofolate reductase genotype, and risk for stroke, vascular dementia, and Alzheimer disease in Northern Ireland

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2005.193

Reduced plasma homocysteine levels in levodopa/entacapone treated Parkinson patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2005.193

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2005.193

Dementia associated with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2005.193

Levodopa-associated increase of homocysteine levels and sural axonal neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2005.193

Plasma homocysteine as a risk factor for dementia and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2005.193

Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2005.193

Parkinsonism: onset, progression, and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2005.193

Elevated plasma homocysteine levels in patients treated with levodopa: association with vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2005.193

21 January 2018

Identifiers

DOI

10.1515/CCLM.2005.193

1 reference

24 December 2017

PubMed ID

16197306

1 reference

24 December 2017